BR112012007239A2 - moléculas de ligação biespecíficas para terapia antiangiogênese - Google Patents

moléculas de ligação biespecíficas para terapia antiangiogênese

Info

Publication number
BR112012007239A2
BR112012007239A2 BR112012007239A BR112012007239A BR112012007239A2 BR 112012007239 A2 BR112012007239 A2 BR 112012007239A2 BR 112012007239 A BR112012007239 A BR 112012007239A BR 112012007239 A BR112012007239 A BR 112012007239A BR 112012007239 A2 BR112012007239 A2 BR 112012007239A2
Authority
BR
Brazil
Prior art keywords
binding molecules
bispecific binding
antiangiogenesis therapy
dii4
vegf
Prior art date
Application number
BR112012007239A
Other languages
English (en)
Inventor
Gschwind Andreas
Van Hoorick Diane
Borges Eric
De Tavernier Evelyn
Boucneau Joachim
Kolkman Joost
Merchiers Pascal
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43431796&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112012007239(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of BR112012007239A2 publication Critical patent/BR112012007239A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)

Abstract

moléculas de ligação biespecíficas para terapia antiangiogênese. a presente invenção refere-se a moléculas de ligação biespecíficas, em particular domínios variáveis isolados de imunoglobulina tais como vhhs e anticorpos de domínio, compreendendo um componente de ligação de vegf e um componente de ligação de dii4 em uma molécula. composições farmacêuticas contendo as mesmas e seu uso no tratamento de doenças que estão associadas com efeitos mediados por vegf e dii4 em angiogênese. ácidos nucleicos codificado as moléculas de ligação bispecíficas, células hospedeiras e métodos para preparar os mesmos.
BR112012007239A 2009-10-02 2010-10-01 moléculas de ligação biespecíficas para terapia antiangiogênese BR112012007239A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09172137 2009-10-02
EP10175316 2010-09-03
PCT/EP2010/064695 WO2011039370A1 (en) 2009-10-02 2010-10-01 Bispecific binding molecules for anti-angiogenesis therapy

Publications (1)

Publication Number Publication Date
BR112012007239A2 true BR112012007239A2 (pt) 2019-09-24

Family

ID=43431796

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012007239A BR112012007239A2 (pt) 2009-10-02 2010-10-01 moléculas de ligação biespecíficas para terapia antiangiogênese

Country Status (23)

Country Link
US (2) US20110172398A1 (pt)
EP (1) EP2483314A1 (pt)
JP (2) JP5833009B2 (pt)
KR (1) KR20120101375A (pt)
CN (2) CN105037542A (pt)
AP (1) AP2012006188A0 (pt)
AR (1) AR078515A1 (pt)
AU (1) AU2010302589A1 (pt)
BR (1) BR112012007239A2 (pt)
CA (1) CA2775422A1 (pt)
CL (1) CL2012000826A1 (pt)
EA (1) EA201200548A1 (pt)
EC (1) ECSP12011835A (pt)
IL (1) IL218542A0 (pt)
IN (1) IN2012DN02752A (pt)
MA (1) MA33607B1 (pt)
MX (1) MX2012003897A (pt)
NZ (2) NZ598956A (pt)
PE (1) PE20121024A1 (pt)
TN (1) TN2012000145A1 (pt)
TW (1) TW201124533A (pt)
UY (1) UY32920A (pt)
WO (1) WO2011039370A1 (pt)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2009003229A (es) 2006-09-29 2009-06-18 Oncomed Pharm Inc Composiciones y metodos para diagnosticar y tratar cancer.
US9029508B2 (en) 2008-04-29 2015-05-12 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
PE20100092A1 (es) 2008-06-03 2010-03-12 Abbott Lab Inmunoglobulina con dominio variable dual y usos de la misma
PE20100054A1 (es) 2008-06-03 2010-03-03 Abbott Lab Inmunoglobulina con dominio variable dual
US8268314B2 (en) 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
US9493545B2 (en) 2009-02-11 2016-11-15 Albumedix A/S Albumin variants and conjugates
CN102459346B (zh) 2009-04-27 2016-10-26 昂考梅德药品有限公司 制造异源多聚体分子的方法
EP3029070A1 (en) 2009-08-29 2016-06-08 AbbVie Inc. Therapeutic dll4 binding proteins
US20110172398A1 (en) * 2009-10-02 2011-07-14 Boehringer Ingelheim International Gmbh Bispecific binding molecules for anti-angiogenesis therapy
ES2895226T3 (es) 2009-10-16 2022-02-18 Mereo Biopharma 5 Inc Combinación terapéutica y uso de anticuerpos antagonistas de DLL4 y agentes antihipertensivos
US8748380B2 (en) 2009-10-30 2014-06-10 Novozymes Biopharma Dk A/S Albumin variants
MY160628A (en) 2010-03-02 2017-03-15 Abbvie Inc Therapeutic DLL4 Binding Proteins
US9428583B2 (en) 2010-05-06 2016-08-30 Novartis Ag Compositions and methods of use for therapeutic low density lipoprotein-related protein 6 (LRP6) multivalent antibodies
BR112012028326A2 (pt) 2010-05-06 2017-03-21 Novartis Ag anticorpo multivalente isolado, anticorpos biparatópicos isolados, ácido nucleico, vetor, composição farmacêutica, método de obtenção dos referidos anticorpos, bem como uso do dos mesmos
EP2824457A1 (en) 2010-07-19 2015-01-14 F. Hoffmann-La Roche AG Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy
MX2013000667A (es) 2010-07-19 2013-02-27 Hoffmann La Roche Metodo para identificar pacientes con probabilidad incrementada de responder a una terapia anticancer.
MY160445A (en) 2010-08-03 2017-03-15 Abbvie Inc Dual Variable Domain Immunoglobulins And Uses Thereof
JP2013539364A (ja) 2010-08-26 2013-10-24 アッヴィ・インコーポレイテッド 二重可変ドメイン免疫グロブリンおよびその使用
US20120225081A1 (en) * 2010-09-03 2012-09-06 Boehringer Ingelheim International Gmbh Vegf-binding molecules
US8551479B2 (en) 2010-09-10 2013-10-08 Oncomed Pharmaceuticals, Inc. Methods for treating melanoma
US20130323265A1 (en) * 2010-11-15 2013-12-05 Oncomed Pharmaceuticals, Inc. Methods for treating cancer with dll4 antagonists
US9527925B2 (en) 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
US20130078247A1 (en) 2011-04-01 2013-03-28 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to dii4 and ang2
AU2015268749B2 (en) * 2011-09-23 2017-05-25 Oncomed Pharmaceuticals, Inc. VEGF/DLL4 binding agents and uses thereof
BR112014007035B1 (pt) 2011-09-23 2021-05-04 Oncomed Pharmaceuticals, Inc anticorpos biespecíficos que se ligam a vegf/dll4, composição farmacêutica e célula procariótica, fúngica ou de levedura que compreende os mesmos, moléculas de polinucleotídeo, vetor, usos terapêuticos e método para a produção de um anticorpo
TW201323442A (zh) 2011-11-04 2013-06-16 Novartis Ag 低密度脂蛋白相關蛋白６（ｌｒｐ６）－半衰期延長構築體
US20140315817A1 (en) 2011-11-18 2014-10-23 Eleven Biotherapeutics, Inc. Variant serum albumin with improved half-life and other properties
EP2797955A2 (en) 2011-12-30 2014-11-05 AbbVie Inc. Dual variable domain immunoglobulins against il-13 and/or il-17
AU2013234299B2 (en) 2012-03-16 2017-06-22 Albumedix Ltd. Albumin variants
HRP20211641T1 (hr) 2012-07-13 2022-02-04 Roche Glycart Ag Bispecifična protutijela anti-vegf/anti-ang-2 i njihova primjena u liječenju vaskularnih očnih bolesti
EA201500370A1 (ru) * 2012-09-28 2015-08-31 Бёрингер Ингельхайм Интернациональ Гмбх ФАРМАЦЕВТИЧЕСКИЕ КОМБИНАЦИИ, СОДЕРЖАЩИЕ ДВОЙНЫЕ АНГИОПОЭТИН-2/Dll4 СВЯЗЫВАЮЩИЕ АГЕНТЫ И АНТИ-VEGF-R АГЕНТЫ
US20140093499A1 (en) * 2012-09-28 2014-04-03 Boehringer Ingelheim International Gmbh Pharmaceutical combinations comprising dual angiopoietin-2 / dll4 binders and anti-vegf agents
US20150368329A1 (en) * 2012-10-15 2015-12-24 Oncomed Pharmaceuticals, Inc. Methods of Treating Ocular Diseases
EP2914961A4 (en) 2012-10-31 2016-04-20 Oncomed Pharm Inc METHODS AND MONITORING A TREATMENT BY AN ANTAGONIST OF DLL4
KR20210111353A (ko) * 2012-11-01 2021-09-10 애브비 인코포레이티드 항-ｖｅｇｆ／ｄｌｌ4 이원 가변 도메인 면역글로불린 및 이의 용도
BR112015009924A2 (pt) * 2012-11-01 2017-12-05 Abbvie Inc formulações de proteína imunoglobulina de domínio variável duplo estáveis
MX2015005363A (es) 2012-11-08 2015-11-06 Novozymes Biopharma Dk As Variantes de albumina.
EP2970459A2 (en) 2013-03-15 2016-01-20 AbbVie Inc. Dual specific binding proteins directed against il-1beta and il-17
EP3020731B1 (en) * 2013-07-09 2019-06-12 ABLBio Novel dual-targeted protein specifically binding to dll4 and vegf, and use thereof
US11185583B2 (en) * 2014-02-11 2021-11-30 Albany Medical College Multi-functional mucosal vaccine platform
EP3125937A4 (en) * 2014-04-04 2017-11-01 Oncomed Pharmaceuticals, Inc. Treatment of gastric cancer
US20170267784A1 (en) 2014-10-23 2017-09-21 Singh Molecular Medicine, Llc Single domain antibodies directed against intracellular antigens
DK3212233T3 (da) 2014-10-31 2020-07-27 Oncomed Pharm Inc Kombinationsterapi til behandling af sygdom
US10093733B2 (en) 2014-12-11 2018-10-09 Abbvie Inc. LRP-8 binding dual variable domain immunoglobulin proteins
WO2016192613A1 (zh) * 2015-06-01 2016-12-08 中山大学 具有融合至常规Fab片段的单域抗原结合片段的二价抗体
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
CA2989966C (en) 2015-08-20 2024-04-30 Albumedix A/S Albumin variants and conjugates
AU2016326609B2 (en) 2015-09-23 2023-03-09 Mereo Biopharma 5, Inc. Methods and compositions for treatment of cancer
TWI746473B (zh) * 2015-11-02 2021-11-21 美商辛分子醫藥有限公司 針對細胞內抗原之單域抗體
CA3009644A1 (en) * 2015-12-04 2017-06-08 The Regents Of The University Of California Novel antibodies for the treatment of cancers
JP6879511B2 (ja) * 2016-01-29 2021-06-02 国立大学法人京都大学 血小板産生促進剤及びそれを用いた血小板の製造方法
CN110831626B (zh) * 2017-01-30 2024-04-19 亚力兄制药公司 单价抗备解素抗体及抗体片段
CA3090321A1 (en) * 2018-02-05 2019-08-08 Stichting Vu Inverse agonistic anti-us28 antibodies
CN111995686B (zh) * 2019-05-27 2022-06-14 兰州大学 一种具有抗血管生成活性的药物及其制备方法
KR20220031044A (ko) * 2019-07-31 2022-03-11 일라이 릴리 앤드 캄파니 릴랙신 유사체 및 이를 사용하는 방법
CN110452297B (zh) * 2019-09-03 2020-04-14 上海洛启生物医药技术有限公司 抗vegf单域抗体及其应用
CN116234574A (zh) * 2020-09-17 2023-06-06 江苏恒瑞医药股份有限公司 特异性结合vegf和ang-2的双特异性抗原结合分子
CN112535738B (zh) * 2020-12-04 2022-09-09 中国科学技术大学 奥沙利铂偶联物及其制备方法和应用
CN115724968B (zh) * 2021-08-27 2023-08-08 三优生物医药(上海)有限公司 Vegf结合分子及其用途
CN116063469B (zh) * 2022-08-29 2023-09-22 中山大学 一种寨卡病毒中和性纳米抗体及其制备方法与应用
WO2024055996A1 (zh) * 2022-09-14 2024-03-21 寻济生物科技（北京）有限公司 一种抗vegfa抗体或其抗原结合片段及其应用
CN117860786B (zh) * 2024-03-12 2024-06-04 北京贝来药业有限公司 基因修饰间充质干细胞在多种疾病中的制药用途和诊断用途

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994004678A1 (en) 1992-08-21 1994-03-03 Casterman Cecile Immunoglobulins devoid of light chains
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
US6329516B1 (en) 1997-04-28 2001-12-11 Fmc Corporation Lepidopteran GABA-gated chloride channels
AU2001259063A1 (en) 2000-04-12 2001-10-30 Human Genome Sciences, Inc. Albumin fusion proteins
CA2433877C (en) 2001-01-17 2014-11-18 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
DK1399484T3 (da) 2001-06-28 2010-11-08 Domantis Ltd Dobbelt-specifik ligand og anvendelse af denne
WO2003059934A2 (en) 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin fusion proteins
WO2004041865A2 (en) 2002-11-08 2004-05-21 Ablynx N.V. Stabilized single domain antibodies
AU2003286004A1 (en) 2002-11-08 2004-06-07 Ablynx N.V. Single domain antibodies directed against interferon- gamma and uses therefor
WO2004060965A2 (en) 2002-12-31 2004-07-22 Nektar Therapeutics Al, Corporation Hydrolytically stable maleimide-terminated polymers
CA2512545C (en) * 2003-01-10 2015-06-30 Karen Silence Recombinant vhh single domain antibody from camelidae against von willebrand factor (vwf)
JP5087274B2 (ja) 2003-06-30 2012-12-05 ドマンティス リミテッド ポリペプチド
JP2007534631A (ja) * 2003-10-28 2007-11-29 ノボ　ノルディスク　アクティーゼルスカブ ラミニン−５γ２結合性ペプチド、その関連組成物およびその使用
EP2251357A1 (en) 2003-11-07 2010-11-17 Ablynx N.V. Camelidae single domain antibodies VHH directed against epidermal growth factor receptor and uses therefor
US20050284249A1 (en) 2004-06-29 2005-12-29 Arnone David F Worm type gear mover assembly
CA2583017A1 (en) 2004-10-13 2006-04-20 Ablynx N.V. Single domain camelide anti-amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenerative neural diseases such as alzheimer's disease
US8048418B2 (en) * 2004-10-29 2011-11-01 Regeneron Pharmaceuticals, Inc. Therapeutic methods for inhibiting tumor growth with combination of Dll4 antagonists and VEGF antagonists
EP2365000A3 (en) 2005-05-18 2013-01-16 Ablynx N.V. Improved nanobodiesTM against tumor necrosis factor-alpha
PL3415535T3 (pl) * 2005-05-20 2021-06-14 Ablynx N.V. Ulepszone Nanociała TM do leczenia zaburzeń, w których pośredniczy agregacja
US7612181B2 (en) * 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
AU2006326417B2 (en) 2005-12-16 2012-05-24 Regeneron Pharmaceuticals, Inc. Therapeutic methods for inhibiting tumor growth with Dll4 antagonists
WO2007143689A2 (en) 2006-06-06 2007-12-13 Genentech, Inc. Compositions and methods for modulating vascular development
ZA200809100B (en) * 2006-06-06 2009-12-30 Genentech Inc Anti-DLL4 antibodies and methods using same
KR20090027227A (ko) 2006-06-06 2009-03-16 제넨테크, 인크. 항-ｄｌｌ4 항체 및 이의 사용 방법
WO2008019144A2 (en) * 2006-08-07 2008-02-14 Regeneron Pharmaceuticals, Inc. Threapeutic methods for treating vascular eye disorders with dll4 antagonists
AU2007285695B2 (en) 2006-08-18 2012-05-24 Ablynx N.V. Amino acid sequences directed against IL-6R and polypeptides comprising the same for the treatment of diseases and disorders associated with IL-6-mediated signalling
WO2008070513A1 (en) * 2006-12-01 2008-06-12 Alcon Research, Ltd. Modulation of polysialylated neural adhesion molecules (psa-ncam) as a regulator of ocular disease
NO347649B1 (no) 2006-12-14 2024-02-12 Regeneron Pharma Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse.
AU2008219216A1 (en) * 2007-02-21 2008-08-28 Ablynx N.V. Amino acid sequences directed against vascular endothelial growth factor and polypeptides comprising the same for the treatment of conditions and diseases characterized by excessive and/or pathological angiogenesis or neovascularization
GB0709333D0 (en) * 2007-05-15 2007-06-20 Smart Targeting Ltd Binding protein
WO2009095489A2 (en) 2008-02-01 2009-08-06 Ablynx N.V. Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling
DE112009000507T5 (de) 2008-03-05 2011-02-10 Ablynx Nv Neue Antigen-bindende Dimerkomplexe, Verfahren zu ihrer Herstellung und ihre Verwendung
EP2947097A1 (en) * 2008-04-07 2015-11-25 Ablynx N.V. Amino acid sequences directed against the Notch pathways and uses thereof
US9029508B2 (en) * 2008-04-29 2015-05-12 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
US8268314B2 (en) * 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
CN102459346B (zh) * 2009-04-27 2016-10-26 昂考梅德药品有限公司 制造异源多聚体分子的方法
US20110172398A1 (en) * 2009-10-02 2011-07-14 Boehringer Ingelheim International Gmbh Bispecific binding molecules for anti-angiogenesis therapy

Also Published As

Publication number Publication date
WO2011039370A1 (en) 2011-04-07
NZ598956A (en) 2014-07-25
CN105037542A (zh) 2015-11-11
IL218542A0 (en) 2012-05-31
CN102639566B (zh) 2015-07-22
IN2012DN02752A (pt) 2015-09-18
CL2012000826A1 (es) 2012-10-19
TN2012000145A1 (en) 2013-09-19
PE20121024A1 (es) 2012-08-10
ECSP12011835A (es) 2012-06-29
AR078515A1 (es) 2011-11-16
JP5833009B2 (ja) 2015-12-16
AU2010302589A1 (en) 2012-04-19
CN102639566A (zh) 2012-08-15
US20110172398A1 (en) 2011-07-14
NZ626302A (en) 2015-09-25
CA2775422A1 (en) 2011-04-07
MX2012003897A (es) 2012-05-08
US20140120095A1 (en) 2014-05-01
AP2012006188A0 (en) 2012-04-30
KR20120101375A (ko) 2012-09-13
TW201124533A (en) 2011-07-16
JP2016026207A (ja) 2016-02-12
EA201200548A1 (ru) 2012-12-28
UY32920A (es) 2011-04-29
MA33607B1 (fr) 2012-09-01
EP2483314A1 (en) 2012-08-08
JP2013506411A (ja) 2013-02-28

Similar Documents

Publication Publication Date Title
BR112012007239A2 (pt) moléculas de ligação biespecíficas para terapia antiangiogênese
BR112013025304A2 (pt) moléculas de ligação biespecíficas que ligam a vegf e ang2
BR112012007294A2 (pt) moléculas de ligação a dll4
CY1122007T1 (el) Μορια δεσμευσης-ang2
UY33588A (es) Moleculas de union a vegf
BR112019010265A2 (pt) anticorpos anti_cd137 inovadores e usos dos mesmos
ECSP14001249A (es) Inmunoenlazadores dirigidos contra el tnf
BR112014029099A2 (pt) anticorpos anti-egfr e seu uso para inibir ou atenuar crescimento de tumor, bem como composição farmacêutica que o compreende
BR112014019611A2 (pt) agentes de ligação mica
BR112012025568A2 (pt) proteínas de ligação ao tnf-<244>.
EA201301109A1 (ru) БИСПЕЦИФИЧЕСКИЕ СВЯЗЫВАЮЩИЕ МОЛЕКУЛЫ, СВЯЗЫВАЮЩИЕСЯ С Dll4 И Ang2
BRPI1007979A2 (pt) Anticorpos anti-mst1r e usos dos mesmos
BR112016014882A2 (pt) Anticorpos monoclonais e processo para produção dos mesmos, composições, usos dos referidos anticorpos e composições, hibridoma murino i-4686, ácido nucleico isolado, vetor, e célula hospedeira

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.